Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent

By Steven Melendez ( April 27, 2012, 8:59 PM EDT) -- A Merck & Co. Inc. unit prevailed Friday in a patent suit against Mylan Pharmaceuticals Inc. over its generic versions of cholesterol drugs Zetia and Vytorin, with a New Jersey federal judge ruling valid Merck's patent on an active ingredient of the drugs. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

This past year, a handful of attorneys secured billions of dollars in settlements and judgments for both classes and individual plaintiffs against massive companies and organizations like Facebook, Dell, the National Association of Realtors, Johnson & Johnson, UFC and Credit Suisse, earning them recognition as Law360's Titans of the Plaintiffs Bar for 2025.